Praxis Precision Medicines Stock Forecast, Price & News

+1.05 (+3.51 %)
(As of 04/13/2021 01:20 PM ET)
Today's Range
Now: $31.00
50-Day Range
MA: $37.03
52-Week Range
Now: $31.00
Volume2,011 shs
Average Volume147,751 shs
Market Capitalization$1.20 billion
P/E RatioN/A
Dividend YieldN/A
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement Purdue Neuroscience Company; and a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc. The company was incorporated in 2015 and is based in Cambridge, Massachusetts.
Praxis Precision Medicines logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:PRAX
Year FoundedN/A



Sales & Book Value

Annual SalesN/A



Market Cap$1.20 billion
Next Earnings Date6/16/2021 (Estimated)
OptionableNot Optionable


Praxis Precision Medicines (NASDAQ:PRAX) Trading 7.7% Higher
April 8, 2021 |
Praxis Precision Medicines (NASDAQ:PRAX) Shares Down 8.1%
April 6, 2021 |
Praxis Precision Medicines (NASDAQ:PRAX) Shares Down 3%
March 31, 2021 |
Praxis Precision Medicines (NASDAQ:PRAX) Stock Price Down 6.8%
March 25, 2021 |
Praxis Precision Medicines (NASDAQ:PRAX) Stock Price Up 5.7%
March 22, 2021 |
Praxis Precision Medicines (NASDAQ:PRAX) Trading Down 15.6%
March 19, 2021 |
See More Headlines


Overall MarketRank

1.67 out of 5 stars

Medical Sector

318th out of 2,016 stocks

Pharmaceutical Preparations Industry

145th out of 771 stocks

Analyst Opinion: 3.5Community Rank: 4.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
+1.05 (+3.51 %)
(As of 04/13/2021 01:20 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PRAX News and Ratings via Email

Sign-up to receive the latest news and ratings for PRAX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Praxis Precision Medicines (NASDAQ:PRAX) Frequently Asked Questions

Is Praxis Precision Medicines a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Praxis Precision Medicines in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Praxis Precision Medicines stock.
View analyst ratings for Praxis Precision Medicines
or view top-rated stocks.

What stocks does MarketBeat like better than Praxis Precision Medicines?

Wall Street analysts have given Praxis Precision Medicines a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Praxis Precision Medicines wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Praxis Precision Medicines?

Praxis Precision Medicines saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 2,020,000 shares, an increase of 129.1% from the March 15th total of 881,700 shares. Based on an average daily trading volume, of 141,700 shares, the short-interest ratio is presently 14.3 days. Currently, 8.4% of the shares of the stock are sold short.
View Praxis Precision Medicines' Short Interest

When is Praxis Precision Medicines' next earnings date?

Praxis Precision Medicines is scheduled to release its next quarterly earnings announcement on Wednesday, June 16th 2021.
View our earnings forecast for Praxis Precision Medicines

How were Praxis Precision Medicines' earnings last quarter?

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) issued its quarterly earnings results on Tuesday, March, 16th. The company reported ($0.87) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by $0.50.
View Praxis Precision Medicines' earnings history

What price target have analysts set for PRAX?

4 Wall Street analysts have issued 1 year target prices for Praxis Precision Medicines' shares. Their forecasts range from $55.00 to $65.00. On average, they anticipate Praxis Precision Medicines' stock price to reach $60.33 in the next twelve months. This suggests a possible upside of 97.7% from the stock's current price.
View analysts' price targets for Praxis Precision Medicines
or view top-rated stocks among Wall Street analysts.

Who are Praxis Precision Medicines' key executives?

Praxis Precision Medicines' management team includes the following people:
  • Dr. Kiran Reddy M.D., Co-Founder & Director (Age 44, Pay $576.59k)
  • Dr. Bernard Ravina, Chief Medical Officer (Age 54, Pay $551.27k)
  • Mr. Marcio Souza, Pres, CEO & Director (Age 42)
  • Dr. David B. Goldstein Ph.D., Co-Founder
  • Dr. Steven Petrou, Co-Founder & Chief Scientific Officer
  • Lauren Mastrocola, VP of Fin., Principal Accounting Officer & Interim Principal Financial Officer
  • Mr. Alex Nemiroff J.D., Gen. Counsel & Sec. (Age 42)
  • Mr. Karl Hansen, Sr. VP of CMC
  • Ms. Nicole Sweeny, Chief Commercial Officer (Age 46)
  • Ms. Alyssa J. S. Wyant, Sr. VP of Regulatory & Quality (Age 46)

Who are some of Praxis Precision Medicines' key competitors?

When did Praxis Precision Medicines IPO?

(PRAX) raised $126 million in an IPO on Friday, October 16th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. Cowen, Evercore ISI, Piper Sandler and Wedbush PacGrow acted as the underwriters for the IPO and Blackstone Capital Markets was co-manager.

What is Praxis Precision Medicines' stock symbol?

Praxis Precision Medicines trades on the NASDAQ under the ticker symbol "PRAX."

When does the company's lock-up period expire?

Praxis Precision Medicines' lock-up period expires on Wednesday, April 14th. Praxis Precision Medicines had issued 10,000,000 shares in its initial public offering on October 16th. The total size of the offering was $190,000,000 based on an initial share price of $19.00. After the end of the company's lock-up period, major shareholders and company insiders will be able to sell their shares of the company.

Who are Praxis Precision Medicines' major shareholders?

Praxis Precision Medicines' stock is owned by a number of institutional and retail investors. Top institutional investors include Pacer Advisors Inc. (0.00%).
View institutional ownership trends for Praxis Precision Medicines

Which institutional investors are buying Praxis Precision Medicines stock?

PRAX stock was acquired by a variety of institutional investors in the last quarter, including Pacer Advisors Inc..
View insider buying and selling activity for Praxis Precision Medicines
or or view top insider-buying stocks.

How do I buy shares of Praxis Precision Medicines?

Shares of PRAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Praxis Precision Medicines' stock price today?

One share of PRAX stock can currently be purchased for approximately $30.52.

How much money does Praxis Precision Medicines make?

Praxis Precision Medicines has a market capitalization of $1.18 billion.

How many employees does Praxis Precision Medicines have?

Praxis Precision Medicines employs 50 workers across the globe.

What is Praxis Precision Medicines' official website?

The official website for Praxis Precision Medicines is

Where are Praxis Precision Medicines' headquarters?

Praxis Precision Medicines is headquartered at 101 MAIN STREET #1210, CAMBRIDGE MA, 02142.

How can I contact Praxis Precision Medicines?

Praxis Precision Medicines' mailing address is 101 MAIN STREET #1210, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-300-8460 or via email at [email protected]

This page was last updated on 4/13/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.